Session VI: Presentation of Selected Non-Colorectal Cancer Abstracts - Esophageal and Stomach Cancers
O-3: Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer
